| 產(chǎn)品名稱 |
LoVo |
| 商品貨號(hào) |
B165000 |
| Organism |
Homo sapiens, human |
| Tissue |
colon; derived from metastatic site: left supraclavicular region |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Dukes' type C, grade IV, colorectal adenocarcinoma |
| Age |
56 years |
| Gender |
male |
| Applications |
This cell line is a suitable transfection host. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Karyotype |
The stemline chromosome number is hyperdiploid with the 2S component occurring at about 2.7% and 3 marker chromosomes were common to all S metaphases. Karyotypes were generally homogeneous and stable. |
| Derivation |
LoVo was initiated in 1971 from a fragment of a metastatic tumor nodule in the left supraclavicular region of a 56-year-old Caucasian male patient with a histologically proven diagnosis of adenocarcinoma of the colon. |
| Clinical Data |
male |
| Antigen Expression |
HLA A11, B15, B17, Cw1, Cw3; blood type B |
| Oncogene |
myc +; myb + ; ras +; fos +; p53 +; sis -; abl -; ros -; src - |
| Genes Expressed |
carcinoembryonic antigen (CEA) 908 ng/10 6 cells/10 days. The cells are negative for expression of CSAp (CSAp-) and colon antigen 3. |
| Cellular Products |
carcinoembryonic antigen (CEA) 908 ng/10 exp6 cells/10 days |
| Tumorigenic |
Yes |
| Effects |
Yes, in nude mice (Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells) |
| Comments |
The cells are negative for expression of CSAp (CSAp-) and colon antigen 3.
The line is positive for expression of c-myc, K-ras, H-ras, N-ras, Myb, sis and fos oncogenes.
N-myc and sis oncogene expression were not detected.
Tumor specific nuclear matrix proteins CC-3 and CC-4 are expressed. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated F-12K Medium, Catalog No. 30-2004. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53mM EDTA solution to remove all traces of serum, which contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:10 is recommended
Medium Renewal: 2 to 3 times per week
|
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37°C
Atmosphere: 95% air, 5% carbon dioxide (CO2) |
| STR Profile |
Amelogenin: XY
CSF1PO: 11,13,14
D13S317: 8, 11
D16S539: 9, 12
D5S818: 11, 12, 13
D7S820: 9.3,10, 11
THO1: 9.3
TPOX: 8,9
vWA: 17,18 |
| Isoenzymes |
ES-D, 1 G6PD, B PGD, A PGM1, 2 PGM3, 1-2 |
| Name of Depositor |
M Romsdahl |
| Deposited As |
Homo sapiens |
| Year of Origin |
1971 |
| References |
Drewinko B, et al. Further biologic characteristics of a human carcinoembryonic antigen-producing colon carcinoma cell line. J. Natl. Cancer Inst. 61: 75-83, 1978. PubMed: 276641
Drewinko B, Yand LY. Restriction of CEA synthesis to the stationary phase of growth of cultured human colon carcinoma cells. Exp. Cell Res. 101: 414-416, 1976. PubMed: 964319
Drewinko B, et al. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 36: 467-475, 1976. PubMed: 1260746
Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874
Keesee SK, et al. Nuclear matrix proteins in human colon cancer. Proc. Natl. Acad. Sci. USA 91: 1913-1916, 1994. PubMed: 8127905
Drewinko B, et al. Response of exponentially growing, stationary-phase, and synchronized cultured human colon carcinoma cells to treatment with nitrosourea derivatives. Cancer Res. 39: 2630-2636, 1979. PubMed: 445465
Miranda L, et al. Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA 93: 7695-7700, 1996. PubMed: 8755538
|
| Cross References |
Nucleotide (GenBank) :
X17097
Human PSG9 mRNA for pregnancy specific glycoprotein 9.
Nucleotide (GenBank) :
X17098
Human PSG10 mRNA for pregnancy specific glycoprotein 10.
Nucleotide (GenBank) :
X14831
Human mRNA for transmembrane carcinoembryonic antigen BGPb (formerly TM2-CEA).
|
